1. Home
  2. EDBL vs CDT Comparison

EDBL vs CDT Comparison

Compare EDBL & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Edible Garden AG Incorporated

EDBL

Edible Garden AG Incorporated

N/A

Current Price

$2.94

Market Cap

1.8M

ML Signal

N/A

Logo Conduit Pharmaceuticals Inc.

CDT

Conduit Pharmaceuticals Inc.

N/A

Current Price

$0.66

Market Cap

2.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EDBL
CDT
Founded
2020
2019
Country
United States
United States
Employees
99
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8M
2.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
EDBL
CDT
Price
$2.94
$0.66
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
75.3K
312.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$29.56
N/A
Revenue Next Year
$20.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.44
$0.37
52 Week High
$7.54
$6.00

Technical Indicators

Market Signals
Indicator
EDBL
CDT
Relative Strength Index (RSI) 54.05 33.84
Support Level $2.49 $0.53
Resistance Level $4.15 $1.16
Average True Range (ATR) 0.27 0.10
MACD -0.14 0.01
Stochastic Oscillator 35.40 15.37

Price Performance

Historical Comparison
EDBL
CDT

About EDBL Edible Garden AG Incorporated

Edible Garden AG Inc is a next-generation controlled environment agriculture farming company. It uses traditional agricultural growing techniques together with technology to grow fresh, organic food, sustainably and safely while improving traceability. The company uses the controlled environment of traditional greenhouse structures, such as glass greenhouses together with hydroponic and vertical greenhouses to sustainably grow organic herbs and lettuces.

About CDT Conduit Pharmaceuticals Inc.

CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Share on Social Networks: